Cargando…

PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis

Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignant disease with 5-year survival rate of less than 6%. Activating mutations of Kras (mu-Kras) are often detected in most of PDAC patients. Although it has been known that oncogenic Kras is the driver of pancreatic cancer initiation and develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Peipei, Wei, Dapeng, Zhang, Hongmei, Chen, Jiao, Zhang, Dingding, Ganapathy, Suthakar, Isakson, Pauline, Chen, Changyan, Zhu, Tongbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132349/
https://www.ncbi.nlm.nih.gov/pubmed/30214681
http://dx.doi.org/10.18632/oncotarget.25127
_version_ 1783354301383442432
author Wang, Peipei
Wei, Dapeng
Zhang, Hongmei
Chen, Jiao
Zhang, Dingding
Ganapathy, Suthakar
Isakson, Pauline
Chen, Changyan
Zhu, Tongbo
author_facet Wang, Peipei
Wei, Dapeng
Zhang, Hongmei
Chen, Jiao
Zhang, Dingding
Ganapathy, Suthakar
Isakson, Pauline
Chen, Changyan
Zhu, Tongbo
author_sort Wang, Peipei
collection PubMed
description Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignant disease with 5-year survival rate of less than 6%. Activating mutations of Kras (mu-Kras) are often detected in most of PDAC patients. Although it has been known that oncogenic Kras is the driver of pancreatic cancer initiation and development, the underlying mechanisms by which mu-Kras promotes PDAC remain poorly understood. Here, we identify that PKCι is one of the crucial factors for supporting the survival of pancreatic cancer cells expressing mu-Kras. Our study demonstrates that after the knockdown of PKCι, the expression of the transcriptional co-activator YAP1 is decreased, which hinders the expression of the downstream target gene Mcl-1, and subsequently sensitizes pancreatic cancer MiaPaCa and PANC-1 cells experssing mu-Kras to apoptosis. In comparison, the suppression of PKCι has little impact on the viability of non-neoplastic pancreatic HPDE6-C7 cells. Moreover, the transient overexpression of oncogenic Kras in HPDE6-C7 elevates the expression of PKCι and YAP1 concomitantly. The upregulated YAP1 in HPDE6-C7/ mu-Kras cells is abolished once PKCι is suppressed, suggesting the linear relationship among mu-Kras, PKCι and YAP1. This phenomenon is further proven by the co-upregulation of PKCι and YAP1 in HPDE6-C7 cells stably transfected with mu-Kras. Taken together, our findings suggest that PKCι acts through promoting YAP1 function to promote the survival of pancreatic cancer cells expressing mu-Kras. It appears that targeting PKCι-YAP1 signaling is a feasible strategy for developing new therapeutics for treating pancreatic cancer patients.
format Online
Article
Text
id pubmed-6132349
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-61323492018-09-13 PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis Wang, Peipei Wei, Dapeng Zhang, Hongmei Chen, Jiao Zhang, Dingding Ganapathy, Suthakar Isakson, Pauline Chen, Changyan Zhu, Tongbo Oncotarget Research Paper Pancreatic ductal adenocarcinoma (PDAC) is a fatal malignant disease with 5-year survival rate of less than 6%. Activating mutations of Kras (mu-Kras) are often detected in most of PDAC patients. Although it has been known that oncogenic Kras is the driver of pancreatic cancer initiation and development, the underlying mechanisms by which mu-Kras promotes PDAC remain poorly understood. Here, we identify that PKCι is one of the crucial factors for supporting the survival of pancreatic cancer cells expressing mu-Kras. Our study demonstrates that after the knockdown of PKCι, the expression of the transcriptional co-activator YAP1 is decreased, which hinders the expression of the downstream target gene Mcl-1, and subsequently sensitizes pancreatic cancer MiaPaCa and PANC-1 cells experssing mu-Kras to apoptosis. In comparison, the suppression of PKCι has little impact on the viability of non-neoplastic pancreatic HPDE6-C7 cells. Moreover, the transient overexpression of oncogenic Kras in HPDE6-C7 elevates the expression of PKCι and YAP1 concomitantly. The upregulated YAP1 in HPDE6-C7/ mu-Kras cells is abolished once PKCι is suppressed, suggesting the linear relationship among mu-Kras, PKCι and YAP1. This phenomenon is further proven by the co-upregulation of PKCι and YAP1 in HPDE6-C7 cells stably transfected with mu-Kras. Taken together, our findings suggest that PKCι acts through promoting YAP1 function to promote the survival of pancreatic cancer cells expressing mu-Kras. It appears that targeting PKCι-YAP1 signaling is a feasible strategy for developing new therapeutics for treating pancreatic cancer patients. Impact Journals LLC 2018-08-28 /pmc/articles/PMC6132349/ /pubmed/30214681 http://dx.doi.org/10.18632/oncotarget.25127 Text en Copyright: © 2018 Wang et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Wang, Peipei
Wei, Dapeng
Zhang, Hongmei
Chen, Jiao
Zhang, Dingding
Ganapathy, Suthakar
Isakson, Pauline
Chen, Changyan
Zhu, Tongbo
PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis
title PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis
title_full PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis
title_fullStr PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis
title_full_unstemmed PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis
title_short PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis
title_sort pkcι and yap1 are crucial in promoting pancreatic tumorigenesis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132349/
https://www.ncbi.nlm.nih.gov/pubmed/30214681
http://dx.doi.org/10.18632/oncotarget.25127
work_keys_str_mv AT wangpeipei pkciandyap1arecrucialinpromotingpancreatictumorigenesis
AT weidapeng pkciandyap1arecrucialinpromotingpancreatictumorigenesis
AT zhanghongmei pkciandyap1arecrucialinpromotingpancreatictumorigenesis
AT chenjiao pkciandyap1arecrucialinpromotingpancreatictumorigenesis
AT zhangdingding pkciandyap1arecrucialinpromotingpancreatictumorigenesis
AT ganapathysuthakar pkciandyap1arecrucialinpromotingpancreatictumorigenesis
AT isaksonpauline pkciandyap1arecrucialinpromotingpancreatictumorigenesis
AT chenchangyan pkciandyap1arecrucialinpromotingpancreatictumorigenesis
AT zhutongbo pkciandyap1arecrucialinpromotingpancreatictumorigenesis